Lipidomics Analysis
Integrated pipeline for lipid identification, classification, pathway mapping, and disease association analysis. Distinct from general metabolomics because lipids have unique classification systems (LIPID MAPS), specialized pathways (sphingolipid, eicosanoid, steroid), and disease associations (cardiovascular, neurodegeneration, metabolic syndrome).
Reasoning Strategy
Lipid identification starts with mass spectrometry: the lipid class is determined by the head group fragment mass (e.g., m/z 184 for phosphocholine in positive mode), total chain length and saturation from the precursor exact mass, and individual fatty acid chains from neutral loss or product ion scans. LIPID MAPS classification organizes lipids by chemical structure into 8 categories — knowing the category immediately tells you the likely biological context (sphingolipids → apoptosis/neurodegeneration; glycerophospholipids → membrane remodeling; eicosanoids → inflammation). Structural specificity matters biologically: Cer(d18:1/16:0) and Cer(d18:1/24:1) have different membrane properties and disease associations despite being the same lipid class. Always map changed lipids back to metabolic pathways because lipids are intermediates — an elevated ceramide could mean increased synthesis (CERS activity up), decreased degradation (ASAH1 down), or shunting from sphingomyelin (SMPD1 up).
LOOK UP DON'T GUESS: Do not assume a lipid's LIPID MAPS ID, exact mass, or pathway membership — query LipidMaps_search_by_name first. Do not guess which diseases are associated with a lipid class; retrieve them from HMDB or CTD.
Key principles:
- LIPID MAPS classification first — use the 8-category system (fatty acyls, glycerolipids, glycerophospholipids, sphingolipids, sterol lipids, prenol lipids, saccharolipids, polyketides)
- Structural specificity matters — chain length, unsaturation, and sn-position affect biological function
- Connect to pathways — lipids are metabolic intermediates; always map to biosynthesis/degradation pathways
- Disease context — many lipids are disease biomarkers (sphingolipids in neurodegeneration, oxidized lipids in CVD)
- Evidence grading — T1: clinical biomarker studies, T2: mechanistic studies, T3: association data, T4: computational prediction
When to Use
- "Identify this lipid species from m/z and retention time"
- "What pathways involve ceramide/sphingomyelin?"
- "Lipid biomarkers for Alzheimer's disease"
- "What diseases are associated with altered sphingolipid metabolism?"
- "Map my lipidomics results to KEGG pathways"
- "Compare lipid profiles between conditions"
Not this skill: For general metabolomics (amino acids, sugars, organic acids), use tooluniverse-metabolomics. For drug ADMET properties, use tooluniverse-admet-prediction.
Core Tools
| Tool |
Use For |
LipidMaps_search_by_name |
Lipid identification by name, abbreviation, or mass |
LipidMaps_get_compound_by_id |
Detailed lipid info (structure, classification, pathways) |
HMDB_search / HMDB_get_metabolite |
Lipid metabolite details, disease associations |
kegg_search_pathway |
Lipid metabolism pathways (keyword=sphingolipid, glycerolipid, etc.) |
KEGG_get_pathway_genes |
Enzymes in lipid pathways |
PubChem_get_compound_properties_by_CID |
Chemical properties (mass, formula, SMILES) |
CTD_get_gene_diseases |
Gene-disease links for lipid metabolism enzymes |
DisGeNET_search_gene |
Disease associations for lipid genes |
PubMed_search_articles |
Published lipidomics studies |
OpenTargets_get_associated_drugs_by_target_ensemblID |
Drugs targeting lipid metabolism enzymes |
Workflow
Phase 0: Lipid Identity Resolution
Name/mass/abbreviation → LIPID MAPS ID → classification
|
Phase 1: Structural Classification
LIPID MAPS 8-category system → subclass → molecular species
|
Phase 2: Pathway Mapping
KEGG lipid metabolism → biosynthesis/degradation enzymes
|
Phase 3: Disease Associations
CTD/DisGeNET/HMDB → lipid-disease links with evidence
|
Phase 4: Interpretation & Report
Biological significance → biomarker potential → recommendations
Phase 0: Lipid Identity Resolution
LipidMaps_search_by_name(query="ceramide") → LMSP ID, exact mass, classification
HMDB_search(compound_name="ceramide") → HMDB ID, disease links
PubChem_get_CID_by_compound_name(name="ceramide") → CID, SMILES
LIPID MAPS search tips:
- Generic names work well: "ceramide", "sphingomyelin", "phosphatidylcholine"
- Species-level abbreviations like "Cer(d18:1/16:0)" may return 0 results — use the generic class name first, then filter by chain length from results
- For exact mass search: use
LipidMaps_search_by_formula with molecular formula (e.g., "C34H67NO3")
- If name search fails, try PubChem:
PubChem_get_CID_by_compound_name(name="C16 Ceramide") then cross-reference
Phase 1: Structural Classification
Use LipidMaps_get_compound_by_id to retrieve the LIPID MAPS 8-category classification (FA, GL, GP, SP, ST, PR, SL, PK) for any lipid. The category immediately signals biological context: SP (sphingolipids) → apoptosis/neurodegeneration; GP (glycerophospholipids) → membrane remodeling; FA-derived eicosanoids → inflammation.
Phase 2: Pathway Mapping
Key lipid metabolism pathways in KEGG:
| Pathway |
KEGG ID |
Key Enzymes |
Disease Relevance |
| Sphingolipid metabolism |
hsa00600 |
SMPD1, CERS1-6, ASAH1 |
Niemann-Pick, Fabry, Gaucher |
| Glycerophospholipid metabolism |
hsa00564 |
PLA2, LPCAT, LPIN |
Barth syndrome, atherosclerosis |
| Arachidonic acid metabolism |
hsa00590 |
COX1/2, LOX, CYP450 |
Inflammation, asthma, CVD |
| Steroid biosynthesis |
hsa00100 |
HMGCR, CYP51A1, DHCR7 |
Hypercholesterolemia, Smith-Lemli-Opitz |
| Fatty acid biosynthesis |
hsa00061 |
FASN, ACC, SCD |
Obesity, NAFLD, cancer |
| Fatty acid degradation |
hsa00071 |
CPT1, ACADM, HADHA |
MCAD deficiency, VLCAD deficiency |
| Bile acid biosynthesis |
hsa00120 |
CYP7A1, CYP27A1 |
Cholestasis, gallstones |
| Ether lipid metabolism |
hsa00565 |
AGPS, GNPAT |
Rhizomelic chondrodysplasia |
# Map lipids to pathways
kegg_search_pathway(keyword="sphingolipid") # → hsa00600
KEGG_get_pathway_genes(pathway_id="hsa00600") # → SMPD1, CERS1, ...
Phase 3: Disease Associations
For each lipid or lipid enzyme, check disease links:
CTD_get_gene_diseases(input_terms="SMPD1") # sphingomyelinase → Niemann-Pick
DisGeNET_search_gene(gene="SMPD1") # broader disease associations
HMDB_get_metabolite(compound_name="ceramide") # metabolite-disease links
PubMed_search_articles(query="ceramide biomarker Alzheimer") # clinical evidence
Disease context: Ceramide elevation → apoptosis, Alzheimer's, insulin resistance. Sphingomyelin depletion → Niemann-Pick. Oxidized phospholipids → CVD. Altered bile acid ratios → NAFLD, cholestasis. Eicosanoid elevation → inflammation. Always verify via HMDB or CTD rather than relying on memory.
Phase 4: Interpretation & Report
Computational procedure: Lipid class enrichment analysis
# When user provides a list of significantly changed lipids
import pandas as pd
from scipy.stats import fisher_exact
# Input: list of changed lipids with LIPID MAPS categories
changed = pd.DataFrame({
'lipid': ['Cer(d18:1/16:0)', 'SM(d18:1/16:0)', 'PC(16:0/18:1)', 'LPC(18:0)'],
'category': ['SP', 'SP', 'GP', 'GP'],
'direction': ['up', 'down', 'unchanged', 'up'],
'fold_change': [2.1, 0.5, 1.1, 1.8]
})
# Count changed vs unchanged per category
from collections import Counter
changed_cats = Counter(changed[changed['direction'] != 'unchanged']['category'])
total_cats = Counter(changed['category'])
# Report
print("Lipid class enrichment:")
for cat in total_cats:
n_changed = changed_cats.get(cat, 0)
n_total = total_cats[cat]
print(f" {cat}: {n_changed}/{n_total} changed")
# Interpretation
if changed_cats.get('SP', 0) / max(total_cats.get('SP', 1), 1) > 0.5:
print("→ Sphingolipid metabolism is significantly altered")
print(" Consider: apoptosis, neurodegeneration, insulin resistance")
Report structure:
- Lipid Identity — LIPID MAPS classification, structural features
- Pathway Context — which metabolic pathways are affected
- Disease Associations — evidence-graded disease links
- Biomarker Assessment — clinical utility of identified lipid changes
- Mechanistic Model — how lipid changes connect to disease biology
- Recommendations — validation experiments, clinical follow-up
Limitations
- No raw MS data processing — this skill interprets identified lipids, not raw spectra. Use LipidSearch, MS-DIAL, or LipiDex for identification first.
- LIPID MAPS coverage — some rare or novel lipid species may not be in the database
- Quantitative thresholds — fold-change cutoffs are context-dependent; the skill provides frameworks, not universal thresholds
- Species-specific — most disease data is human; rat/mouse lipid metabolism can differ significantly
1---
2name: tooluniverse-lipidomics
3description: Lipid analysis and lipid-disease associations using LIPID MAPS classification, HMDB metabolite data, KEGG/Reactome lipid pathways (sphingolipid, eicosanoid, steroid, fatty acid), and PubChem chemical info. Use for lipid identification, lipid metabolism pathway mapping, and lipid-associated disease analysis (cardiovascular, diabetes, NAFLD).
4disable-model-invocation: true
5---
6
7# Lipidomics Analysis
8
9Integrated pipeline for lipid identification, classification, pathway mapping, and disease association analysis. Distinct from general metabolomics because lipids have unique classification systems (LIPID MAPS), specialized pathways (sphingolipid, eicosanoid, steroid), and disease associations (cardiovascular, neurodegeneration, metabolic syndrome).
10
11## Reasoning Strategy
12
13Lipid identification starts with mass spectrometry: the lipid class is determined by the head group fragment mass (e.g., m/z 184 for phosphocholine in positive mode), total chain length and saturation from the precursor exact mass, and individual fatty acid chains from neutral loss or product ion scans. LIPID MAPS classification organizes lipids by chemical structure into 8 categories — knowing the category immediately tells you the likely biological context (sphingolipids → apoptosis/neurodegeneration; glycerophospholipids → membrane remodeling; eicosanoids → inflammation). Structural specificity matters biologically: Cer(d18:1/16:0) and Cer(d18:1/24:1) have different membrane properties and disease associations despite being the same lipid class. Always map changed lipids back to metabolic pathways because lipids are intermediates — an elevated ceramide could mean increased synthesis (CERS activity up), decreased degradation (ASAH1 down), or shunting from sphingomyelin (SMPD1 up).
14
15**LOOK UP DON'T GUESS**: Do not assume a lipid's LIPID MAPS ID, exact mass, or pathway membership — query `LipidMaps_search_by_name` first. Do not guess which diseases are associated with a lipid class; retrieve them from HMDB or CTD.
16
17**Key principles**:
181. **LIPID MAPS classification first** — use the 8-category system (fatty acyls, glycerolipids, glycerophospholipids, sphingolipids, sterol lipids, prenol lipids, saccharolipids, polyketides)
192. **Structural specificity matters** — chain length, unsaturation, and sn-position affect biological function
203. **Connect to pathways** — lipids are metabolic intermediates; always map to biosynthesis/degradation pathways
214. **Disease context** — many lipids are disease biomarkers (sphingolipids in neurodegeneration, oxidized lipids in CVD)
225. **Evidence grading** — T1: clinical biomarker studies, T2: mechanistic studies, T3: association data, T4: computational prediction
23
24---
25
26## When to Use
27
28- "Identify this lipid species from m/z and retention time"
29- "What pathways involve ceramide/sphingomyelin?"
30- "Lipid biomarkers for Alzheimer's disease"
31- "What diseases are associated with altered sphingolipid metabolism?"
32- "Map my lipidomics results to KEGG pathways"
33- "Compare lipid profiles between conditions"
34
35**Not this skill**: For general metabolomics (amino acids, sugars, organic acids), use `tooluniverse-metabolomics`. For drug ADMET properties, use `tooluniverse-admet-prediction`.
36
37---
38
39## Core Tools
40
41| Tool | Use For |
42|------|---------|
43| `LipidMaps_search_by_name` | Lipid identification by name, abbreviation, or mass |
44| `LipidMaps_get_compound_by_id` | Detailed lipid info (structure, classification, pathways) |
45| `HMDB_search` / `HMDB_get_metabolite` | Lipid metabolite details, disease associations |
46| `kegg_search_pathway` | Lipid metabolism pathways (keyword=`sphingolipid`, `glycerolipid`, etc.) |
47| `KEGG_get_pathway_genes` | Enzymes in lipid pathways |
48| `PubChem_get_compound_properties_by_CID` | Chemical properties (mass, formula, SMILES) |
49| `CTD_get_gene_diseases` | Gene-disease links for lipid metabolism enzymes |
50| `DisGeNET_search_gene` | Disease associations for lipid genes |
51| `PubMed_search_articles` | Published lipidomics studies |
52| `OpenTargets_get_associated_drugs_by_target_ensemblID` | Drugs targeting lipid metabolism enzymes |
53
54---
55
56## Workflow
57
58```
59Phase 0: Lipid Identity Resolution
60 Name/mass/abbreviation → LIPID MAPS ID → classification
61 |
62Phase 1: Structural Classification
63 LIPID MAPS 8-category system → subclass → molecular species
64 |
65Phase 2: Pathway Mapping
66 KEGG lipid metabolism → biosynthesis/degradation enzymes
67 |
68Phase 3: Disease Associations
69 CTD/DisGeNET/HMDB → lipid-disease links with evidence
70 |
71Phase 4: Interpretation & Report
72 Biological significance → biomarker potential → recommendations
73```
74
75### Phase 0: Lipid Identity Resolution
76
77```
78LipidMaps_search_by_name(query="ceramide") → LMSP ID, exact mass, classification
79HMDB_search(compound_name="ceramide") → HMDB ID, disease links
80PubChem_get_CID_by_compound_name(name="ceramide") → CID, SMILES
81```
82
83**LIPID MAPS search tips**:
84- Generic names work well: "ceramide", "sphingomyelin", "phosphatidylcholine"
85- Species-level abbreviations like "Cer(d18:1/16:0)" may return 0 results — use the generic class name first, then filter by chain length from results
86- For exact mass search: use `LipidMaps_search_by_formula` with molecular formula (e.g., "C34H67NO3")
87- If name search fails, try PubChem: `PubChem_get_CID_by_compound_name(name="C16 Ceramide")` then cross-reference
88
89### Phase 1: Structural Classification
90
91Use `LipidMaps_get_compound_by_id` to retrieve the LIPID MAPS 8-category classification (FA, GL, GP, SP, ST, PR, SL, PK) for any lipid. The category immediately signals biological context: SP (sphingolipids) → apoptosis/neurodegeneration; GP (glycerophospholipids) → membrane remodeling; FA-derived eicosanoids → inflammation.
92
93### Phase 2: Pathway Mapping
94
95Key lipid metabolism pathways in KEGG:
96
97| Pathway | KEGG ID | Key Enzymes | Disease Relevance |
98|---------|---------|-------------|-------------------|
99| Sphingolipid metabolism | hsa00600 | SMPD1, CERS1-6, ASAH1 | Niemann-Pick, Fabry, Gaucher |
100| Glycerophospholipid metabolism | hsa00564 | PLA2, LPCAT, LPIN | Barth syndrome, atherosclerosis |
101| Arachidonic acid metabolism | hsa00590 | COX1/2, LOX, CYP450 | Inflammation, asthma, CVD |
102| Steroid biosynthesis | hsa00100 | HMGCR, CYP51A1, DHCR7 | Hypercholesterolemia, Smith-Lemli-Opitz |
103| Fatty acid biosynthesis | hsa00061 | FASN, ACC, SCD | Obesity, NAFLD, cancer |
104| Fatty acid degradation | hsa00071 | CPT1, ACADM, HADHA | MCAD deficiency, VLCAD deficiency |
105| Bile acid biosynthesis | hsa00120 | CYP7A1, CYP27A1 | Cholestasis, gallstones |
106| Ether lipid metabolism | hsa00565 | AGPS, GNPAT | Rhizomelic chondrodysplasia |
107
108```python
109# Map lipids to pathways
110kegg_search_pathway(keyword="sphingolipid") # → hsa00600
111KEGG_get_pathway_genes(pathway_id="hsa00600") # → SMPD1, CERS1, ...
112```
113
114### Phase 3: Disease Associations
115
116For each lipid or lipid enzyme, check disease links:
117
118```python
119CTD_get_gene_diseases(input_terms="SMPD1") # sphingomyelinase → Niemann-Pick
120DisGeNET_search_gene(gene="SMPD1") # broader disease associations
121HMDB_get_metabolite(compound_name="ceramide") # metabolite-disease links
122PubMed_search_articles(query="ceramide biomarker Alzheimer") # clinical evidence
123```
124
125**Disease context**: Ceramide elevation → apoptosis, Alzheimer's, insulin resistance. Sphingomyelin depletion → Niemann-Pick. Oxidized phospholipids → CVD. Altered bile acid ratios → NAFLD, cholestasis. Eicosanoid elevation → inflammation. Always verify via HMDB or CTD rather than relying on memory.
126
127### Phase 4: Interpretation & Report
128
129**Computational procedure: Lipid class enrichment analysis**
130
131```python
132# When user provides a list of significantly changed lipids
133import pandas as pd
134from scipy.stats import fisher_exact
135
136# Input: list of changed lipids with LIPID MAPS categories
137changed = pd.DataFrame({
138 'lipid': ['Cer(d18:1/16:0)', 'SM(d18:1/16:0)', 'PC(16:0/18:1)', 'LPC(18:0)'],
139 'category': ['SP', 'SP', 'GP', 'GP'],
140 'direction': ['up', 'down', 'unchanged', 'up'],
141 'fold_change': [2.1, 0.5, 1.1, 1.8]
142})
143
144# Count changed vs unchanged per category
145from collections import Counter
146changed_cats = Counter(changed[changed['direction'] != 'unchanged']['category'])
147total_cats = Counter(changed['category'])
148
149# Report
150print("Lipid class enrichment:")
151for cat in total_cats:
152 n_changed = changed_cats.get(cat, 0)
153 n_total = total_cats[cat]
154 print(f" {cat}: {n_changed}/{n_total} changed")
155
156# Interpretation
157if changed_cats.get('SP', 0) / max(total_cats.get('SP', 1), 1) > 0.5:
158 print("→ Sphingolipid metabolism is significantly altered")
159 print(" Consider: apoptosis, neurodegeneration, insulin resistance")
160```
161
162**Report structure**:
1631. **Lipid Identity** — LIPID MAPS classification, structural features
1642. **Pathway Context** — which metabolic pathways are affected
1653. **Disease Associations** — evidence-graded disease links
1664. **Biomarker Assessment** — clinical utility of identified lipid changes
1675. **Mechanistic Model** — how lipid changes connect to disease biology
1686. **Recommendations** — validation experiments, clinical follow-up
169
170---
171
172## Limitations
173
174- **No raw MS data processing** — this skill interprets identified lipids, not raw spectra. Use LipidSearch, MS-DIAL, or LipiDex for identification first.
175- **LIPID MAPS coverage** — some rare or novel lipid species may not be in the database
176- **Quantitative thresholds** — fold-change cutoffs are context-dependent; the skill provides frameworks, not universal thresholds
177- **Species-specific** — most disease data is human; rat/mouse lipid metabolism can differ significantly